SCHEMBL16635697

SCHEMBL16635697

COC(=O)C1CCCCC1c1csc(N2CCC(F)(F)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 5/20 0.42
CTSS P25774 5/20 0.42
CTSK P43235 5/20 0.42
KCNH2 Q12809 3/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 1/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 3/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
USP2 O75604 1/20 0.37
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
KDM1A O60341 1/20 0.35
CRBN Q96SW2 1/20 0.34
WHR1 P49842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635696 1.00 CTSB (0.42) CTSBCTSSCTSKKCNH2SLC6A2
SCHEMBL16635719 0.87 CTSB (0.43) CTSBCTSSCTSKKCNH2SMN1; SMN2
SCHEMBL16636003 0.78 HRH3 (0.37) CTSBCTSSCTSKKCNH2SLC6A2
SCHEMBL16636001 0.78 HRH3 (0.37) CTSBCTSSCTSKKCNH2SLC6A2
SCHEMBL16636565 0.78 SLC6A2 (0.39) SLC6A2SLC6A4SMN1; SMN2ALDH1A1LMNA
SCHEMBL16636564 0.78 SLC6A2 (0.39) SLC6A2SLC6A4SMN1; SMN2ALDH1A1LMNA
SCHEMBL16636099 0.75 SLC6A2 (0.45) SLC6A2SLC6A4SMN1; SMN2ALDH1A1MAPK1
SCHEMBL2555286 0.72 CRBN (0.58) SMN1; SMN2ALDH1A1MAPK1LMNAMAPT
SCHEMBL16635783 0.70 SLC6A2 (0.46) SLC6A2SLC6A4LMNATP53
SCHEMBL16635781 0.70 SLC6A2 (0.46) SLC6A2SLC6A4LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSB 1/4885CTSS 2/4885CTSK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.